베타 차단제 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the beta blockers market size is projected to be USD 11 billion in 2025, USD 11.5 billion in 2026, and reach USD 14 billion by 2031, growing at a CAGR of 4.01% from 2026 to 2031.

This report is Segmented by Drug Class (Beta-1 Selective, and More), Molecule (Metoprolol, Bisoprolol, Atenolol, and More), Route of Administration (Oral, Intravenous, Ophthalmic), Indication (Hypertension, Heart Failure, Arrhythmias, and More), Distribution Channel (Hospital, Retail, Online), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Beta Blockers Market Trends and Insights

Foundational Role in Heart Failure and Post-Infarction Care Anchors Long-Term Demand

Guidelines from the Japanese Circulation Society in 2025 maintained Class I recommendations for beta blockers alongside renin-angiotensin and sodium-glucose cotransporter-2 inhibitors, reinforcing universal inclusion in quadruple therapy . Landmark trials such as MERIT-HF continue to inform reimbursement audits that link hospital payments to beta-blocker prescription rates in North America and Europe. The European Society of Cardiology's 2024 atrial-fibrillation guideline still positions beta blockers ahead of calcium-channel blockers for rate control in impaired left-ventricular function. Mortality benefits after acute coronary syndrome remain robust, sustaining formulary preference in emergency pathways. As a result, long-term utilization in heart-failure and post-myocardial-infarction patients continues to outweigh the volume lost from uncomplicated hypertension.

Cardiovascular Disease Burden Sustains Chronic Prescribing Despite Guideline Shifts

World Health Organization statistics place global cardiovascular deaths at 19.8 million in 2022, with hypertension and coronary disease leading the etiology. The American Heart Association 2025 update cited 122.4 million U.S. adults with hypertension, populations in which beta blockers remain either preferred add-ons or first-line for compelling indications. Real-world registries from India show beta-blocker penetration exceeding 75% across major cardiovascular admissions, validating continued physician reliance even where local guidelines lag European and U.S. revisions. These prevalence dynamics, especially in Asia-Pacific and MEA, underpin sustained baseline demand and compensate for the gradual pullback in initial hypertension prescriptions

Guideline Revisions Narrow First-Line Hypertension Use

The 2024 European Society of Cardiology hypertension guideline removed beta blockers from standard first-line therapy in patients without compelling cardiac indications . The 2025 American Heart Association update echoed this stance after meta-analyses showed superior stroke prevention with renin-angiotensin and calcium-channel inhibitors. Clinical-decision-support platforms across Europe and the United States implemented the change within months, immediately influencing prescribing behavior in primary care settings. Although Asia-Pacific and MEA countries have not yet updated local algorithms, multinational companies report lower hypertension-only initiation rates in mature markets, trimming near-term growth in the beta blockers market.

Other drivers and restraints analyzed in the detailed report include:

1. Ultra-Short-Acting Intravenous Formulations Expand Critical-Care Utility
2. Extended-Release Formulations and Fixed-Dose Combinations Lift Adherence Metrics
3. Prostaglandin Analogs Capture First-Line Glaucoma Share

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cardioselective molecules such as metoprolol, bisoprolol, and nebivolol captured 62.18% of 2025 revenue, and this share of the beta blockers market is projected to expand at a 4.35% CAGR through 2031. Cardioselectivity mitigates the risk of bronchospasm in patients with reactive airway disease, thereby widening the eligible heart-failure and post-infarction populations. Nebivolol's nitric-oxide stimulation lowers peripheral resistance, driving its status as the fastest-rising molecule within the class. Nonselective agents retain relevance in portal hypertension prophylaxis and ophthalmology, while carvedilol and labetalol serve heart failure and emergent hypertensive crises, respectively.

Physician preference for cardioselective therapy is also guided by payer quality metrics that benchmark bronchospasm-related readmissions. European narrow-spectrum reimbursement lists grant small price premiums for bisoprolol based on the CIBIS-II mortality record, whereas North American formularies emphasize interchangeability, reinforcing high generic substitution rates. As outcome-based reimbursement spreads to emerging economies, the performance edge of cardioselective drugs is expected to secure steady expansion in the beta blockers market.

Oral tablets accounted for 78.19% of 2025 prescriptions, representing the largest share of the beta blocker market in chronic therapy. Once-daily extended-release designs reduce peak-to-trough variability, enhancing tolerability and adherence. Intravenous formulations are recording a 4.21% CAGR, driven by the perioperative and intensive-care requirements for rapid on-off hemodynamic control. Hospitals increasingly favor landiolol for its ultra-short profile when managing heart rate during transcatheter interventions.

Topical ophthalmic solutions are declining in stand-alone use but remain part of fixed-dose prostaglandin combinations. Regulatory barriers are comparatively higher for IV and combination products, as bioequivalence studies must confirm immediate systemic availability or additive efficacy. Manufacturers that can navigate these pathways hold an advantage in differentiated, higher-margin sub-segments of the beta blockers market.

Geography Analysis

North America generated 33.18% of 2025 revenue, aided by Medicare Part D coverage, heart-failure quality metrics, and high penetration of extended-release formulations. The Centers for Medicare & Medicaid Services financially reward hospitals that meet beta-blocker prescription benchmarks, ensuring stable institutional demand. Canada's provincial formularies preferentially reimburse generics, compressing brand premiums.

Asia-Pacific is the fastest-growing region, with a 4.30% CAGR. India's ROBUST registry recorded metoprolol use in over three-quarters of cardiovascular discharges, and China's volume-based procurement lists metoprolol at prices below USD 0.05 per tablet, an environment favoring vertically integrated firms. Japan and South Korea show rising heart-failure prevalence, but prostaglandin analogs are cannibalizing topical beta-blocker sales in glaucoma.

Europe's market is mature and price-sensitive due to parallel trade and aggressive tendering, yet volumes remain resilient thanks to national heart-failure initiatives. German physicians retain loyalty to Concor bisoprolol, while the United Kingdom's National Health Service mandates generic substitution. Southern European austerity continues to channel prescriptions toward the lowest-cost suppliers. Middle East & Africa and South America lag in share but show potential as insurance coverage widens through public-private partnerships.

1. Abbvie
2. Accord Healthcare
3. Alcon
4. ANI Pharmaceuticals
5. AOP Orphan Pharmaceuticals GmbH
6. Apotex
7. Aurobindo Pharma
8. Bausch Health
9. Baxter
10. Cipla
11. Dr. Reddy's Laboratories Ltd.
12. Fresenius
13. Glenmark Pharmaceuticals
14. Hikma Pharmaceuticals
15. Lupin
16. Menarini Industrie Farmaceutiche Riunite S.R.L.
17. Merck
18. Sandoz Group
19. Santen Pharmaceuticals
20. Sun Pharmaceuticals Industries
21. Teva Pharmaceutical Industries
22. Torrent Pharmaceuticals Limited
23. Viatris
24. Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Foundational Role in HFrEF, AF Rate Control, And Post-MI Care Maintained in Leading Guidelines
  • 4.2.2 Hypertension And Ischemic Heart Disease Prevalence Sustaining Chronic Beta-Blocker Prescriptions
  • 4.2.3 Growing Glaucoma and Ocular Hypertension Pool Supporting Ophthalmic Beta-Blocker Demand
  • 4.2.4 Expansion Of Ultra-Short-Acting IV Beta-1 Blockers (Esmolol, Landiolol) In ICU/Perioperative Settings
  • 4.2.5 ER/CR And Fixed-Dose Combinations Improving Adherence and Persistence
  • 4.2.6 Portal Hypertension Prophylaxis Broadening Noncardiac Use of Nonselective Beta Blockers
• 4.3 Market Restraints
  • 4.3.1 Deprioritization As First-Line in Uncomplicated Hypertension in Updated Guidelines
  • 4.3.2 Prostaglandin Analogs Favored as First-Line in Glaucoma, Lowering Beta-Blocker Initiation
  • 4.3.3 Global Generic Price Erosion and Tendering Pressure Compress Margins
  • 4.3.4 Sterile Injectable Shortages and API Supply Risks Constrain Hospital Availability
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Beta-1 Selective
  • 5.1.2 Nonselective
  • 5.1.3 Combined Alpha/Beta
• 5.2 By Molecule
  • 5.2.1 Metoprolol
  • 5.2.2 Bisoprolol
  • 5.2.3 Atenolol
  • 5.2.4 Nebivolol
  • 5.2.5 Carvedilol
  • 5.2.6 Others
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Intravenous
  • 5.3.3 Ophthalmic (topical)
• 5.4 By Indication
  • 5.4.1 Hypertension
  • 5.4.2 Heart failure (HFrEF)
  • 5.4.3 Arrhythmias (AF/SVT Rate Control)
  • 5.4.4 Angina & Ischemic Heart Disease
  • 5.4.5 Other Indications
• 5.5 By Distribution Channel
  • 5.5.1 Hospital pharmacies
  • 5.5.2 Retail Pharmacies and Drug Stores
  • 5.5.3 Online / E-pharmacies
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of APAC
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of MEA
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
  • 6.3.1 AbbVie Inc.
  • 6.3.2 Accord Healthcare
  • 6.3.3 Alcon Inc
  • 6.3.4 ANI Pharmaceuticals, Inc.
  • 6.3.5 AOP Orphan Pharmaceuticals GmbH
  • 6.3.6 Apotex Inc.
  • 6.3.7 Aurobindo Pharma Limited
  • 6.3.8 Bausch & Lomb
  • 6.3.9 Baxter International Inc.
  • 6.3.10 Cipla Inc.
  • 6.3.11 Dr. Reddy's Laboratories Ltd.
  • 6.3.12 Fresenius Kabi AG
  • 6.3.13 Glenmark Pharmaceuticals
  • 6.3.14 Hikma Pharmaceuticals
  • 6.3.15 Lupin Limited
  • 6.3.16 Menarini Industrie Farmaceutiche Riunite S.R.L.
  • 6.3.17 Merck KGaA
  • 6.3.18 Sandoz AG
  • 6.3.19 Santen Pharmaceutical Co., Ltd.
  • 6.3.20 Sun Pharmaceutical Industries
  • 6.3.21 Teva Pharmaceutical Industries
  • 6.3.22 Torrent Pharmaceuticals Limited
  • 6.3.23 Viatris Inc.
  • 6.3.24 Zydus Lifesciences Limited

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment